Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses

Pandey, Aseem; Singh, Neetu; Mittal, Suresh K.

doi:10.4161/hv.6.2.9899

Cited by 52 publications

(49 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A method based on embryonated chicken eggs is commonly used to produce influenza vaccines. However, this method requires about 4 ~ 6 months for vaccine production, which could be fatal in a pandemic [2,3]. Supplying sufficient embryonated chicken eggs might also be difficult in the case of an emergency, or may be inappropriate if the influenza strains to be vaccinated against are lethal to birds [4].…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, new eggindependent strategies are required for the production of influenza vaccines. Several egg-independent methods of vaccine production, including cell-culture-derived whole virus or subvirion vaccines, recombinant-protein-based vaccines, virus-like-particle vaccines, and DNA vaccines, have been developed [2,5]. Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of native viruses [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Production of influenza virus-like particles from stably transfected Trichoplusia ni BT1 TN-5B1-4 cells

Hong

Park

Lee

et al. 2015

Biotechnol Bioproc E

View full text Add to dashboard Cite

We investigated the production of influenza A/ Korea/01-2-9/2009 (H1N1) virus-like particles (VLPs) containing four structural proteins, matrix protein 1 (M1), matrix protein 2 (M2), neuraminidase (NA) and hemagglutinin (HA), using stably transfected Trichoplusia ni BT1 TN-5B1-4 (TN-5B1-4) cells. Recombinant M1, M2, NA and HA were expressed as bands with molecular weights of 28, 17, 60, and 70 kDa, respectively, in stably transfected TN-5B1-4 (TN-5B1-4/M1-M2-NA-HA) cells. VLPs were purified from the culture medium of the TN-5B1-4/M1-M2-NA-HA cells by pelleting on a sucrose cushion, followed by ultracentrifugation in a sucrose density gradient. The four structural proteins were released together from the TN-5B1-4/M1-M2-NA-HA cells, and were co-purified from the same fractions of the sucrose density gradient, indicating that recombinant M1, M2, NA, and HA self-assembled into VLPs in the TN-5B1-4/M1-M2-NA-HA cells. Recombinant baculoviruses (rBac/NA and rBac/HA) expressing recombinant NA and HA were generated and used to co-infect stably transfected TN-5B1-4 (TN-5B1-4/M1-M2) cells expressing recombinant M1 and M2, resulting in the production of high-molecularweight VLPs and the release of self-assembled VLPs with diameters of 80 ~ 120 nm. The production of VLPs was greatly enhanced in the TN-5B1-4/M1-M2 cells co-infected with rBac/NA and rBac/HA, compared with the TN-5B1-4/M1-M2-NA-HA cells. Our results suggest that a stably transfected-insect cell expression system might be useful for producing VLPs for the development of recombinant vaccines against influenza.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Production of influenza virus-like particles from stably transfected Trichoplusia ni BT1 TN-5B1-4 cells

Hong

Park

Lee

et al. 2015

Biotechnol Bioproc E

View full text Add to dashboard Cite

show abstract

“…10 Current production capacity provides vaccines for approximately 800 million doses, 11,12 but protection from pandemic disease resulting from antigen shift will require greater production capacity. 13 Ideally, a pandemic response should also not compete for production of seasonal vaccines. 12 For example, the preventive vaccine requirements for a potentially emerging influenza such as H7N9 14 could still pose a significant production challenge.…”

Section: Introductionmentioning

confidence: 99%

Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge

Mallajosyula

Hiatt

Hume

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Second, the enormous potential of rapid and scalable transient expression systems has been recognized in the context of emergency medical responses and other time-critical applications, such as antibodies for active and passive immunotherapy. Notable examples include ZMapp, a cocktail of three monoclonal antibodies for the treatment of Ebola virus disease, 66 the use of plants to produce seasonal and emergency influenza vaccines, 98,99 which normally takes more than 6 months to stockpile using the traditional system based on chicken eggs, 100 and the individualized autologous idiotypic cancer vaccines produced for non-Hodgkin's lymphoma patients. 76,77 In addition to the speed, scale, and economy, plants also benefit Figure 2.…”

Section: Why Make Antibodies In Plants?mentioning

confidence: 99%

Antibodies from plants for bionanomaterials

Edgue

Twyman²,

Beiss

et al. 2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Antibodies are produced as part of the vertebrate adaptive immune response and are not naturally made by plants. However, antibody DNA sequences can be introduced into plants, and together with laboratory technologies that allow the design of antibodies recognizing any conceivable molecular structure, plants can be used as 'green factories' to produce any antibody at all. The advent of plant-based transient expression systems in particular allows the rapid, convenient, and safe production of antibodies, ranging from laboratory-scale expression to industrial-scale manufacturing. The key features of plant-based production include safety, speed, low cost, and convenience, allowing newcomers to rapidly master the technology and use it to its full advantage. Manufacturing in plants has recently achieved significant milestones and offers more than just an alternative to established microbial and mammalian cell platforms. The use of plants for product development in particular offers the power and flexibility to easily coexpress many different genes, allowing the plug-and-play construction of novel bionanomaterials, perfectly complementing existing approaches based on plant virus-like particles. As well as producing single antibodies for applications in medicine, agriculture, and industry, plants can be used to produce antibody-based supramolecular structures and scaffolds as a new generation of green bionanomaterials that promise a bright future based on clean and renewable nanotechnology applications. © 2017 The Authors. WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals, Inc. How to cite this article:WIREs Nanomed Nanobiotechnol 2017, 9:e1462. doi: 10.1002/wnan.1462 INTRODUCTIONA ntibodies are glycoproteins produced by the adaptive immune system in humans and other vertebrates. They recognize and bind particular target antigens with great affinity and specificity, allowing them to clear pathogens and other unwanted material from the body. Although plants do not naturally produce antibodies, they can be engineered to do so by introducing the corresponding immunoglobulin genes. 1,2 In this manner, plants can be instructed to make antibodies that target any antigen of choice, and they can make them efficiently and in all kinds of different formats. 3,4 Most people picture antibodies as the typical mammalian serum-type immunoglobulin G (IgG), which comprises two identical heavy chains and two identical light chains joined by disulfide bonds (Figure 1). The chains fold and assemble into a multimeric Y-shaped structure. Below the hinge, in what is known as the Fc region (fragment crystallizable), all IgG molecules are largely the same, and this region is responsible for the general effector functions of antibodies, such as immune cell recognition and complement fixation. This part of the antibody is also glycosylated. The hinge and the region above, where the antibody branches into its characteristic Y-shape, is known as the F(ab 0 ) 2 or Fab (fragment for antigen This is an open access article under ...

show abstract

Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses

Cited by 52 publications

References 121 publications

Production of influenza virus-like particles from stably transfected Trichoplusia ni BT1 TN-5B1-4 cells

Production of influenza virus-like particles from stably transfected Trichoplusia ni BT1 TN-5B1-4 cells

Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge

Antibodies from plants for bionanomaterials

Contact Info

Product

Resources

About